Study claiming target in sepsis with erythromycin has no effect upon mortality and secondary outcomes includes patients with CRRT and RRT.
(2023) Critical Care — Vol. 27, n° 1, p. 52 [1-2] (2023)
Files
HonorePCritCare2023.pdf
Open Access - Adobe PDF
- 576.15 KB
Details
- Authors
- Abstract
- (en) Reijnders et al. recently published an article concluding that, in their target trial emulation on critically ill patients with sepsis, they could not demonstrate an effect of treatment with low-dose erythromycin on mortality, secondary clinical outcomes, or host response biomarkers. However, when carefully reviewing the baseline characteristics, we found that 49.8% of the patients in the treated group had acute kidney injury (AKI). [...]
- Affiliations
Citations
Honoré, P., Blackman, S., Perriens, E., & Bousbiat, I. (2023). Study claiming target in sepsis with erythromycin has no effect upon mortality and secondary outcomes includes patients with CRRT and RRT. Critical Care, 27(1), 52 [1-2]. https://doi.org/10.1186/s13054-023-04335-7 (Original work published 2023)